摘要
目的:观察威麦宁胶囊联合卡培他滨治疗晚期乳腺癌的临床效果及安全性。方法:回顾性分析2013年1月—2016年6月在本院乳腺外科治疗的100例晚期乳腺癌患者。所有患者均服用威麦宁胶囊,一次6~8粒,3次/d。卡培他滨1250 mg/m2,分2次口服,d1~d14,治疗两周,停药1周,21 d为1个治疗周期,连续治疗2个周期以上。观察患者的治疗周期、无进展生存期(PFS)、总体生存期(OS)以及药物不良反应。结果:患者的平均治疗周期为6.5(2~12)个周期;平均治疗时间为4.5(1.4~8.4)个月;平均PFS为6.8(1.5~15.3)个月;平均OS为14.9(2.5~21.1)月。最常见的不良反应为贫血、骨髓抑制、高血压。总缓解率为80%(95%CI 1.78~5.69)。其中10例完全缓解;70例部分缓解。结论:威麦宁胶囊联合卡培他滨治疗晚期乳腺癌具有一定的疗效,耐受性高,值得在临床大力推广应用。
Objective:To observe the clinical effect and safety of Weimaining Capsule combined with capecitabine in the treat- ment of advanced breast cancer. Methods:A retrospective analysis of January 2013 to June 2016 in our hospital breastsurgerydep- artment of 100 patients with advanced breast cancer was carried out. All patients were given Weimaining Capsule,6 -8 tablets, 3 times a day, Capecitabine 1250 mg/m2 , twice a day orally, dl - d14. The continuous treatment lasted for 2 weeks and then stopping the administration for 1 week,21 d for a treatment cycle, continuous treatment for more than 2 cycles. The progression -free survival (PFS) ,overall survival (OS) and adverse drug reactions were observed. Results:The average treatment cycle was 6.5 (2 - 12). The average treatment time was 4.5 ( 1.4 - 8.4) months. The average PFS was 6.8 ( 1.5 - 15.3) months. The aver- age OS was 14.9 (2.5 - 21.1 ) months. The most common adverse reactions are anemia, myelosuppressionand hypertension. The overall response rate was 80% (95% CI 1.78 -5.69). there were 10 cases completed relievered and 70 cases partially relievered. Conclusion : Weimaining Capsule combined with capecitabine in the treatment of advanced breast cancer has a certain effect and high tolerance. It is worth to promote the clinical application.
出处
《辽宁中医杂志》
CAS
北大核心
2017年第12期2588-2590,共3页
Liaoning Journal of Traditional Chinese Medicine
基金
四川省科技厅与泸州市政府
泸州医学院联合课题(201414JC0197-LH38)
关键词
乳腺癌
威麦宁胶囊
卡培他滨
breast cancer
Weimaining Capsule
capecitabine